Efprezimod Alfa

CD24Fc · Oncoimmune, Inc., a subsidiary of Merck & Co., Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Efprezimod Alfa, covering 2020-01-29 to 2022-11-14. Get the full timeline:

Most recent: Clinical Trial Update: Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) [Phase 3]

See pricing